

ORIGINAL ARTICLE

Insulin Resistance and Lipid Profile in Rheumatoid Arthritis Patients in Bangladesh

Farhana Alam¹, Shahela Sultana Chowdhury², Rumana Ishrat³, Tahrim Mehdi⁴, Ruksana Karim⁵

Abstract:

There has been a great deal of research activity focusing on the relationship between insulin resistances (IR), hyperlipidemia and Rheumatic arthritis (RA). It appears to be a general agreement that IR and hyperlipidaemia are commonly seen in patients with RA. A case-control study was done among 45 RA patients and 42 healthy controls. The study was conducted in the outpatient department of Bangabandhu Sheikh Mujib Medical University (BSMMU). A structured questionnaire was used to collect data through face-to-face interview. TG and LDL were significantly higher and HDL was lower in comparison to those of control and associated with IR. Hyperlipidemias are associated with RA in Bangladeshis.

Introduction:

Rheumatoid arthritis (RA) is a systemic immune and chronic inflammatory disease. Its prevalence is remarkably consistent worldwide. Its prevalence is 0.6% in Bangladeshi population¹ and 0.8% in western population. In addition to articular manifestations of RA, there is growing recognition of excess mortality, which is predominantly due to increased coronary artery atherosclerosis².

Rheumatoid arthritis is now considered as an important component of metabolic syndrome. RA patients experience a markedly increased prevalence of cardiovascular disease³, a comorbidity that may be partly mediated through insulin resistance⁴. An independent association of insulin resistance with carotid as well as coronary artery atherosclerosis has been reported in RA⁵. Insulin resistance (IR) seems to be the main metabolic abnormality that alters glucose metabolism, decreases the sensitivity of peripheral tissues to insulin in patients with rheumatoid arthritis and complicating rheumatic disease via an increase in atherosclerotic disease risk and pre-diabetic state⁶.

In RA, the primary site of inflammation is the synovial tissue, from which cytokines can be released into the systemic circulation. Insulin insensitivity also shows cytokine production and other markers of inflammation. Pro-inflammatory cytokines like Interleukin-1, Interleukin-6 and Tumor necrosis factor – α

1. Associate Professor, Department of Biochemistry, Community Medical College Hospital, Dhaka.
2. Assistant Professor, Department of Biochemistry, Community Medical College Hospital, Dhaka.
3. Assistant Professor, Department of Biochemistry, Kumudini Womens Medical College Hospital, Mirzapur.
4. Assistant Professor, Department of Biochemistry, Bangabandhu Sheikh Mujib Medical University, Dhaka.
5. Associate Professor, Department of Biochemistry, Uttara Adhunic Medical College Hospital, Dhaka.

(TNF- α) are major modulators of these events. TNF- α leading to accumulation of serum triglycerides and decrease in serum HDL cholesterol and increased LDL cholesterol might be result of hampered insulin action⁷. Under their influence, elevation of blood lipids, enhanced gluconeogenesis, catabolic hormone production and decreased insulin sensitivity occurs. Similar events, however, occur during the course of inflammatory diseases such as RA^{8,9}. In RA patients, disease activity is associated with elevated levels of LDL and insulin resistance¹⁰.

Thus, in western population it is evident that hyperlipidaemia seems to be an important feature in insulin resistant RA patients. So far, in Bangladesh, no study has yet been done to explore the role of hyperlipidaemia and insulin resistance, in rheumatic arthritis patients. The present study has been undertaken to evaluate the association of IR and lipid profile among RA patients.

Materials and method:

The present case-control study was carried out in the department of biochemistry of BSMMU. In this study, 87 subjects with age ranged from 34-45 years of both sexes were included. Among them 45 patients were of RA fulfilling the American College of Rheumatology (ACR) criteria. The RA patients were further divided into two groups; untreated group of 19 RA patients and treated group of 26 patients who were on disease modifying anti-rheumatic agents (DMARD). Forty two apparently healthy volunteers, not having DM and MI, were also selected as control. The objectives and benefits of the study were explained to all the subjects to

ensure their voluntary participation and written informed consent was taken from each subject prior to the study.

From each subject, blood was drawn for determination of IR and lipid profile. IR was calculated from fasting plasma glucose (mmol/l) and fasting serum insulin (pmol/l) values by the Homeostasis Model Assessment (HOMA) model, using HOMA-2 software¹¹. Plasma total cholesterol was measured by enzymatic endpoint method (cholesterol oxides / peroxides). Plasma triglyceride was measured by enzymatic colorimetric (GPO-PAP) method. Plasma high density lipoprotein (HDL-c) was measured by enzymatic colorimetric (cholesterol CHOD-PAP) method. Plasma LDL-cholesterol level was calculated by using Friedewald's formula.

Statistical analysis was done using SPSS software for Windows version 12.0. Data were expressed as Mean \pm SD, Median (Range) or as number (%). Statistical significance of differences between mean and median values was assessed by Student's unpaired t-test, Mann-Whitney U-test, where appropriate. A two-tailed p-value of < 0.05 was considered statistically significant.

Results:

The study subjects were age and BMI matched. RA patients with treatment showed significantly higher triglyceride $z=0.02$ and RA patients without treatment showed significantly higher triglyceride $z=0.009$ than the controls and in RA patients with treated vs untreated. Lower high-density lipoprotein (HDL) in treated RA group and in untreated RA group than the controls and in RA patients with treated vs. untreated. Results are

expressed as mean \pm SD. Unpaired Student's t-test was done.

Table-I: Age and BMI distribution of the study subjects

Study subjects	Age in years	BMI
RA patients (n = 45)	33.89 \pm 10.89	22.17 \pm 4.34
Control (n = 42)	31.79 \pm 9.22	22.67 \pm 3.7
Test of significance t / P	0.97 / 0.34	0.58 / 0.56

have abnormal lipid profiles as evidenced by global reduction of all lipid subsets and also increased triglyceride¹¹. Some studies report the disease activity of RA is associated with both low LDL and HDL cholesterol and both lipoproteins increase upon suppression of disease activity¹².

Reason behind such findings in Bangladeshi patients can be due to different food habit, life style etc. Replacing carbohydrates by monounsaturated fats as a source of calories

Table II: Comparison of lipid profile and insulin resistance

Parameters	With treatment (n=26)	Without treatment (n=19)	Control (n=42)	Test of Significance z / p		
				Control vs treated	Control vs untreated	treated vs untreated
T. Cholesterol	173(120-259)	176(130-225)	170(125-273)	.207/.836	.745/.456	.548/.583
TG	110(52-185)	139(42-320)	93(34-262)	2.20/0.02	2.62/0.009	1.25/.20
HDL	25(17-37)	26(15-37)	38(24-51)	5.6/0.0001	5.04/0.0001	1.31/.18
LDL	123(62-200)	120(87-178)	115(40-199)	1.03/.30	.99/.32	.28/.77
HOMA%B	88 (1-238)	105(33-303)	91(47-189)	.64 /.51	.55/.57	1.05/.29
HOMA%S	141(27-317)	121(35-315)	140 (24-289)	.03/.97	1.5 / .11	.98/.32

Results are expressed as Median (range). Mann-Whitney test was done. n= number of subjects.

RA= Rheumatoid arthritis; TG= Triglyceride; HDL= High density lipoprotein; LDL= Low density lipoprotein

Discussion:

Insulin resistance has been considered as a main metabolic abnormality in patients with RA leading to alteration in glucose metabolism caused by decreased sensitivity of peripheral tissues to insulin. In western population, it is evident that IR seems to be an important feature in RA patients^{7,11}. Association between IR and lipid profile in RA subjects was evaluated in this study.

In this study, IR was associated with higher level of cholesterol, higher triglycerides and lower HDL level in RA patients. These findings are supported by many studies where it has been found that patients with active RA

raises HDL- cholesterol without effecting LDL- cholesterol and also improve insulin sensitivity. For conclusive results, further study with greater population with dietary intervention is recommended.

References:

1. Haq SA. Prevalence of rheumatic diseased and associated outcome in rural and urban communities in Bangladesh: A COPCORD Study. J Rheumatology 2005; 32: 552-556.
2. Dessein PH, Joffe BI, Stanwix AE. Inflammation, insulin resistance and aberrant lipid metabolism as

- cardiovascular risk factors in rheumatoid arthritis. *The Journal of Rheumatology* 2003; 39: 321-324.
3. Maradit-kremers H , Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. *Arthritis Rheum* 2005; 52: 722-732.
 4. Sattar N, McCaarey DW, Capell H, McInnes IB. Expaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. *Circulation* 2003; 108: 2957-2963.
 5. Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. *J Rheumatol* 2006; 33: 2425-2432.
 6. Top C, Tuncel A, Özkan OS, Kocak N, Cavuslu S, Danaci M, et al. The Correlation of insulin resistance with serum TNF- α levels in patients with rheumatoid arthritis. *The Internet Journal of Rheumatology* 2002; 1: 1528-4812.
 7. Dessein PH, Joffe BI, Stanwix AE. The acute phase response does not fully predict the presence of insulin resistance dyslipidemia in inflammatory arthritis. *The Journal of Rheumatology* 2002; 29: 462-465.
 8. Fernandez R, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. *Endocrine Reviews* 2003; 24: 278-301.
 9. Fernandez-Real, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. *Endocrine Reviews* 2003; 24: 278-301.
 10. Fernandez-Real, Ricart W. Insulin resistance and inflammation in an evolutionary perspective; the contribution of cytokine genotype / phenotype to thriftiness. *Diabetologia* 1999; 42: 1367-1374.
 11. Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA et al. Effect of disease modifying agents on the lipid profiles of patients with Rheumatoid arthritis: *Ann Rheum Dis* 1997; 56: 3774-3776.
 12. Caumo A, Perseghin G, Brunani A, Luzi L. New insights on the simultaneous assessment of insulin sensitivity and β -cell function with the HOMA2 method. *Diabetes Care* 2006; 29: 2733-2734.